

4 **Phytochemical and Pharmacological Potential of *Enhydra fluctuans* available**
5 **in Bangladesh**

6
7
8 **ABSTRACT**

9 **Objective:**

10 The possible phytochemical nature, thrombolytic and membrane stabilizing activity of the crude
11 ethanolic extract of *Enhydra fluctuans*(CE) were investigated along with the anti-microbial,
12 antioxidant and cytotoxic potentials of its petroleum ether (PESF), carbon tetrachloride (CTCSF),
13 chloroform (CSF) and aqueous (AQSF) soluble fractions.

14 **Materials & Methods:**

15 The coarse leaf powder was extracted at room temperature with ethanol. Solvent-solvent
16 partitioning was done to obtain the four soluble fractions by the modified Kupchan method.
17 Anticoagulant potential was determined by the *invitro* thrombolytic model, membrane
18 stabilization method was used to assess *in vitro* anti-inflammatory activity, the disc diffusion
19 method was used for anti-microbial screening, antioxidant potential was determined by 2,2-
20 diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method and brine shrimp lethality bioassay
21 method was used for cytotoxic activity determination.

22 **Results:**

23 Chemical screening of the crude extract evidences the presence of alkaloids, saponins, tannins,
24 flavonoids, reducing sugars and gums. It showed significant clot lysis property of 49.29%. It also
25 significantly inhibited heat and hypotonic solution induced lysis of the human red blood cell
26 membrane with values of 71.67% and 47.93%, respectively. CTCSF and PESF showed mild
27 antimicrobial activity. AQSF showed most prominent antioxidant activity with IC₅₀ value of
28 12.27 µg/mL. CTCSF showed LC₅₀ value of 0.84 µg/mL, with most potent cytotoxic activity.

29 **Conclusion:**

30 Significant thrombolytic, membrane stabilizing, antioxidant and cytotoxic activities of the plant
31 was found from this study. *In vivo* activities and isolation of active compound(s) from this
32 extract are yet to be investigated.

33 **Keywords:** *Enhydra fluctuans*, thrombolytic activity, membrane stabilizing activity, antioxidant
34 activity and cytotoxic activity.

35
36 **INTRODUCTION**

37 Medicinal plants have played an important role in treating various diseases since ancient times.
38 Increased drug resistance and side effects of existing pharmaceutical drugs have escalated the
39 research based study on traditionally available plants.

40 Myocardial or cerebral infraction and other atherothrombotic diseases are consequences of
41 thrombus formed in blood vessel^{1,2}. Fibrinolytic drugs like tissue plasminogen activator (t-PA),
42 urokinase, streptokinase etc. dissolve thrombin in acutely occluded coronary arteries and restore
43 blood supply to ischemic myocardium, to limit necrosis and improve prognosis³. Yet all the
44 available thrombolytic agents have significant deficiencies, including the necessity of large doses
45 to be maximally effective, limited fibrin specificity and a significant associated bleeding
46 tendency. Therefore, studies are going on to develop improved thrombolytic drugs in order to
47 minimize deficiencies of the available drugs.

48 Inflammation is a pathological disorder, in which inflammatory cells produce a complex mixture
49 of growth and differentiation cytokines as well as physiologically active arachidonate
50 metabolites, also generate reactive oxygen species (ROS) that can damage cellular biomolecules
51 which in turn augment the state of inflammation⁴. Compounds that possess radical scavenging
52 ability may therefore expect to have the therapeutic potentials against inflammation⁵. Moreover,
53 stabilization of lysosomal membrane limits inflammatory response by inhibiting the release of
54 lysosomal constituents of activated neutrophil such as bactericidal enzymes and proteases, which
55 are responsible for further tissue inflammation and damage⁶.

56 Bacteria are responsible for many infectious diseases in 21st century⁷. Antibiotic resistance has
57 become a major clinical and public health problem for most people now-a-days^{8,9}. This
58 Multidrug Resistance (MDR) is clearly related to the misuse of different antibiotics^{10,11}. The
59 increasing clinical importance of drug resistant bacterial pathogens necessitates emergence
60 of additional antibacterial therapy. The antibacterial screening which is the first stage of
61 antibacterial research is performed to ascertain the susceptibility of various bacteria to any agent.

62 Free radicals are highly toxic and reactive; and cause diseases like aging, atherosclerosis, cancer,
63 diabetes, liver cirrhosis, cardiovascular disorders, etc. by attacking different macro-molecules
64 including lipids, proteins and DNA resulting in the cellular damage^{12,13}. Antioxidants protect
65 body by delaying or reducing the oxidation of the substrate in turn neutralize or terminate the
66 chain reaction before vital molecules within the body are damaged¹⁴. Currently available
67 synthetic antioxidants like butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT),
68 tertiary butylated hydroquinone and gallic acid esters show low solubility and moderate
69 antioxidant activity with suspected negative health effects¹⁵. BHA and BHT are suspected of
70 being responsible for liver toxicity and carcinogenesis^{16,17}. Investigations to screen out naturally
71 occurring antioxidants are now mostly demanding.

72 Bioactive compounds are always toxic to living body at some higher doses and it justifies the
73 statement that 'Pharmacology is simply toxicology at higher doses and toxicology is simply
74 pharmacology at lower doses'. Brine shrimp lethality bioassay implies cytotoxicity as well as a
75 wide range of pharmacological activities such as antimicrobial, antiviral, pesticidal and anti-
76 tumor etc. of the compounds^{18,19}.

77 *Enhydra fluctuans* Lour (Family: Asteraceae) is a small genus of marsh herb, available in
78 tropical and subtropical regions; like Bangladesh, India, Malaysia, China and the rest of South
79 East Asia and Tropical Africa^{20,21}. The herb is relatively glabrous sometimes pubescent
80 glandular. Stems are usually 0.3-0.6m, elongated simple or divaricating rooting at the nodes²².

81 Traditional uses indicate that the leaves of the plant are good as laxative. The expressed juice of
82 the leaves is an excellent demulcent in gonorrhoea and also used in the treatment of skin and
83 nervous system²³. These activities can be attributed mainly to the presence of phytochemicals
84 such as flavonoids, alkaloids, saponins, tannins, phenols and carbohydrates. But there are
85 insufficient records in literature of this plant, regarding its pharmacological activities and
86 phytochemical characteristics. Thus the present study focuses on screening of the ethanolic
87 extract of *Enhydra fluctuans* Lour for its phytochemical and pharmacological potential.

88
89
90

91 **MATERIALS AND METHODS**

92 *Instrumentation*

93 The extract was condensed in rotary vacuum evaporator (Heidolph Instruments GmbH & Co.
94 KG, Germany). Samples were centrifuged on a bench top centrifuge machine (HERMLE
95 Labortechnik GmbH, Germany). The absorbance was recorded by a UV-Visible
96 spectrophotometer (Analytic Jena AG, Germany). Ketoconazole was obtained from Beximco
97 Pharmaceuticals Ltd., Bangladesh. Streptokinase vial (Beacon Pharmaceutical Ltd) was
98 purchased from local pharmacy. Trolox and BHA were obtained from Calbiochem, Merck,
99 Germany and VWR International Ltd., England, respectively. Nutrient agar and potato dextrose
100 agar and Kanamycin 30 µg standard disc were purchased from HiMedia Laboratories Pvt. Ltd.,
101 India. All other reagents were purchased from Sigma-Aldrich, USA and all other solvents used
102 were of analytical grade and purchased from Active Fine Chemicals Ltd., Bangladesh.

103 *Collection and Identification*

104 For this investigation, *Enhydra fluctuans* leaves were collected from Narayangonj, Bangladesh
105 on February 2015. Plant was identified by experts. After collection leaves were thoroughly
106 washed with clean water then shade dried for several days and oven dried for 24 hours at not
107 more than 40 °C for better grinding. The dried leaves were then ground to a coarse powder. The
108 powder(140 g) was subjected to cold maceration by soaking in 1200 mL of ethanol in a clean,
109 amber colored reagent bottle. The container was kept for a period of 10 days with occasional
110 shaking and stirring. The whole mixtures were then filtered through a fresh cotton plug and
111 finally with a Whatman No.1 filter paper. The filtrate was concentrated at 40°C under reduced
112 pressure to evaporate approximately 70% of the solvent to obtain the crude extract, CE. 5.0 g of
113 CE was dissolved in 10% aqueous ethanol. Solvent-solvent partitioning of this solution was done
114 using the protocol designed by Kupchan and modified by Van Wagenen et al., (1993) with
115 petroleum ether, then with carbon tetrachloride and finally with Chloroform to obtain three
116 fractions (PESF, CTCF and CSF) and the remaining part was named as aqueous soluble
117 fraction (AQSF)²⁴.

118 *Phytochemical Screening*

119 Approximately 5 mg of CE was diluted in ethanol to perform the following tests for identification
120 of different chemical groups^{25,26}.

121 *Tests for tannins*

122 Ferric Chloride Test: 5 mL of the solution was taken in a test tube. 1 mL of 5% ferric chloride
123 solution was added to it. Greenish black precipitate will indicate the presence of tannins.

124 Potassium Dichromate Test: 1 mL of 10% potassium dichromate solution was added with 5 mL
125 of the extract solution in a test tube. Yellow precipitate will suggest the presence of tannins.

126 Lead Acetate Test: 1 mL of 10% lead acetate solution was added to 5 mL of extract
127 solution. Presence of tannins will be indicated by yellow precipitate.

128 ***Test for Flavonoids***

129 A few drops of concentrated hydrochloric acid were added to a small amount of CE. Immediate
130 red color formation is caused by flavonoids.

131

132 ***Test for Saponins***

133 1 mL of the solution was diluted with distilled water to 20 mL and shaken in a graduated
134 cylinder for 15 minutes. One-centimeter layer of foam formation will indicate the presence of
135 saponins.

136 ***Tests for Gums***

137 5 mL solution of the extract was taken and then molisch reagent and sulfuric acid were added.
138 Red violet ring at the junction of the two liquids evidences presence of gums.

139 ***Tests for Steroids***

140 1 mL concentrated sulphuric acid was added to 1 mL solution of the chloroform extract. Red
141 color in the lower layer will indicate the presence of steroids.

142 ***Tests for alkaloids***

143 Mayer's test: 2 mL solution and 0.2 mL of dilute hydrochloric acid were taken in a test tube. Then
144 1 mL of Mayer's reagent was added. Yellowish buff colored precipitate is indicative of presence
145 of alkaloids.

146 Dragendroff's test: 2 mL solution and 0.2 mL of dilute hydrochloric acid were taken in a test
147 tube. Then 1 mL of Dragendroff's reagent was added. Orange brown precipitate evidences the
148 presence of alkaloids.

149 Hager's test: 2 mL solution of the extract and 0.2 mL of dilute hydrochloric acid were taken in a
150 test tube. Then 1 mL of picric acid solution or Hager's reagent was added. Yellowish precipitate
151 evidences presence of alkaloids.

152 ***Test for Reducing Sugar***

153 2 mL of aqueous extract of the plant material was added to 1 mL of a mixture of equal volumes
154 of Fehling's solutions A and B, boiled for few minutes. Brick red colored precipitate will
155 indicate presence of reducing sugar.

156 ***Thrombolytic activity***

157 As a part of exploration of cardio protective drugs from natural resources the extract of *E.*
158 *fluctuans* was assessed for thrombolytic activity using *in vitro* thrombolytic model²⁷. Taking
159 account of all ethical considerations, and aseptic precautions 20 mL of venous blood was drawn

160 from healthy human volunteer without a history of oral contraceptive or anticoagulant therapy.
161 This withdrawn blood was then distributed in pre-weighed sterile vials (1 mL/tube) and incubated
162 at 37 °C for 45 minutes. After clot formation, the serum was completely removed without
163 disturbing the clot and clot weight was determined (clot weight = weight of clot containing vial –
164 weight of vial alone). 100 mg of CE was dissolved in 10 mL of ethanol and kept overnight. Then
165 the soluble supernatant was decanted and filtered. 100 µL of the solution was added to a vial
166 containing pre-weighed clot. Lyophilized Streptokinase (SK) vial of 15,00,000 I.U. was
167 reconstituted with 5 ml sterile distilled water. 100 µL (30,000 I.U) of the solution was added as
168 positive control and 100 µL of distilled water was added as a negative non thrombolytic control
169 to the vial containing pre-weighed clot separately. All the three vials were then incubated at 37
170 °C for 90 minutes and observed for clot lysis. After incubation, the released fluid was removed
171 and vials were again weighed to observe the weight difference after clot disruption. This
172 difference of weight before and after clot lysis was expressed as percentage of clot lysis as
173 shown below:

174 **% of clot lysis = (wt. of released clot/clot wt.) × 100**

175 *Membrane stabilization activity*

176 To assess the anti-inflammatory activity membrane stabilization potential of CE was evaluated
177 by measuring the heat and hypotonic solution induced haemolysis of erythrocyte following
178 standard protocol²⁸.

179 *Preparation of erythrocyte suspension*

180 Fresh whole blood (20 mL) was collected intravenously in syringe containing 3.1% sodium
181 citrate solution as anticoagulant from healthy human volunteer without history of non steroidal
182 anti-inflammatory drugs (NSAIDs) therapy for 2 weeks prior the experiment. The blood cells
183 were washed three times with isotonic buffer solution, 154 mM NaCl in 10 mM sodium
184 phosphate buffer (pH 7.4) through centrifugation at 3000 g for 10 min.

185 *Heat induced haemolysis*

186 CE was dissolved in isotonic solution. Isotonic buffer containing aliquots (5 mL) of the extract at
187 1.0 mg/mL was taken in 6 centrifuge tubes in three sets of two. Two sets of control tubes were
188 taken containing 5 mL of the vehicle and 5 mL of 0.1 mg/mL of acetyl salicylic acid (ASA),
189 respectively. Erythrocyte suspension was added to each tube and mixed gently by inversion. One
190 pair of the tubes was incubated at 56°C for 30 min in a water bath, while the other pair was
191 maintained at (0-5) °C in an ice bath. The reaction mixture was centrifuged for 5 min at 2500g
192 and the absorbance of the supernatant was measured at 560 nm. The percentage inhibition or
193 acceleration of hemolysis was calculated according to the equation:

194 % Inhibition of hemolysis = $100 \times [1 - (OD_2 - OD_1) / (OD_3 - OD_1)]$

195 Where,

196 OD₁ = optical density of unheated test sample; OD₂ = optical density of heated test sample; OD₃ =
197 optical density of heated control sample

198 *Hypotonic solution induced haemolysis*

199 5 mL hypotonic solution (distilled water) containing 1.0 mg/mL of CE were put in centrifuge
200 tube in triplicates. 5 mL of hypotonic solution and 5 mL of acetyl salicylic acid (ASA) at 0.1

201 mg/mL concentration was taken as negative and positive control respectively in separate
202 centrifuge tubes. Erythrocyte suspension (0.5 mL) was added to each of the tubes and mixed
203 gently. The mixture was incubated for 10 min at room temperature and then centrifuged for 10
204 min at 3000 g. The absorbance of the supernatant was measured at 540 nm. The percentage
205 inhibition of haemolysis or membrane stabilization was calculated using the following equation:

$$206 \text{ Inhibition of haemolysis (\%)} = 100 [1 - \{(OD_2 - OD_1) / (OD_3 - OD_1)\}]$$

207 Where OD_1 = absorbance of test sample in isotonic solution; OD_2 = absorbance of test sample in
208 hypotonic solution; OD_3 = absorbance of control hypotonic sample

209 *Antimicrobial assay*

210 The disc diffusion technique²⁹ was used for preliminary screening of antimicrobial activity. Two
211 Gram Positive bacterial strains (*Bacillus megaterium*, *Staphylococcus aureus*), two Gram
212 Negative bacterial strains (*Escherichia coli*, *Pseudomonas aeruginosa*) and two fungal strains
213 (*Aspergillus niger* and *Aspergillus flavus*) were collected as pure cultures. PESF, CTCSF, CSF,
214 AQSF fractions of the crude extract were dissolved separately in specific volume of
215 dichloromethane or methanol depending on their solubility. The diluted samples were applied on
216 the sterile discs at a concentration of 500 µg/disc. Kanamycin (30 µg/disc) and Ketoconazole (30
217 µg/disc) were used as standard antibiotics for antibacterial and antifungal screening, respectively.
218 Solvent was used as negative control. The antimicrobial activity of the test agent was determined
219 by measuring the diameter of zone of inhibition expressed in millimeter.

220 *Antioxidant scavenging activity*

221 Antioxidant potential was studied using DPPH radical scavenging activity with slight
222 modification of the method described by Brand-William *et al*³⁰. Here, solution of varying
223 concentrations such as 200 µg/mL, 100 µg/mL, 50 µg/mL, 25 µg/mL, 12.5 µg/mL, 6.25 µg/mL,
224 3.125 µg/mL, 1.5625 µg/mL and 0.78125 µg/mL were obtained by serial dilution technique in
225 test tubes where 2 mL of each of the test sample solution was mixed with 2 mL of a DPPH-
226 methanol solution (20 µg/mL) to obtain the above mentioned concentrations. Test tubes were
227 allowed to stand for 20 minutes in dark for the reaction to occur. The absorbance was determined
228 at 517 nm and percentage of inhibition was calculated by using the following equation:

229

$$230 \text{ \% inhibition} = [1 - (ABS_{\text{sample}} / ABS_{\text{control}})] \times 100.$$

231

232 Then % inhibitions were plotted against respective concentrations used and from the graph IC_{50}
233 was calculated. Here, ascorbic acid and BHA were used as the positive control.

234 *Cytotoxic activity*

235 Brine shrimp lethality bioassay technique was applied for the determination of general toxic
236 properties of the plant extractives against *Artemiasalina*^{19,31}. The test samples were dissolved in
237 dimethyl sulfoxide (DMSO) following serial dilutions to obtain concentrations of 400, 200, 100,
238 50, 25, 12.5, 6.25 and 3.125 µg/mL in separate test tubes containing 10 shrimps in simulated
239 brine water (5 mL). The test tubes were incubated at room temperature for 24 hours. The LC_{50} of
240 the test samples was determined by a plot of percentage of the shrimp mortality against the

241 logarithm of the sample concentrations. Vincristine sulphate was used as positive control in this
242 assay to compare the cytotoxicity of the test samples.

243

244

245

246

247

248

249

250

251 **RESULT AND DISCUSSION**

252 *Phytochemical screening*

253 Preliminary phytochemical screening evidences the presence of alkaloids, saponin, tannins,
254 flavonoids, reducing sugar and gums (Table1).


255 Table 1: Results of chemical group tests

Tested groups	Alkaloids	Steroids	Saponin	Tannins	Flavonoids	Reducing Sugars	Gums
Ethanollic Extract of <i>Enhydrafluctuans</i>	+	-	+	+	+	+	+

256 *Note: + =Indicates the presence of the tested group, - = Indicates the absence of the tested*
257 *group.*

258 *Thrombolytic activity*

259 The erythrocyte membrane resembles to lysosomal membrane and as such, the effect of drugs on
260 the stabilization of erythrocyte could be extrapolated to the stabilization of
261 lysosomal membrane^{32,33}. Addition of 100µL SK solution, a positive control to the clots and
262 subsequent incubation resulted in 66.67% lysis of clot. On the other hand, negative control
263 exhibited a negligible lysis of clot (8.33%). When clots were treated with the test sample
264 significant clot lysis activity (46.91%) was observed. When compared with the negative control
265 (water) the mean of percentage (%) of clot lysis was significant ($p < 0.001$).



266
 267 Figure 1:Thrombolytic activity (in terms of % of clot lysis) of CE with standard deviation error
 268 bar where n=3

269 *Membrane stabilizing activity*

270 Flavonoid rich ethyl acetate extract of *E. fluctuans* collected from West Bengal, India showed
 271 significant anti-inflammatory activity in carrageenan and histamine induced paw edema in rats³⁴.
 272 The ethanol extracts of *E. fluctuans* at concentration 1.0mg/mL significantly protected the lysis
 273 of human erythrocyte membrane by hypotonic solution and heat induced haemolysis compared
 274 to the standard acetyl salicylic acid (0.10mg/ml). For heat induced condition CE demonstrated
 275 71.80% inhibition of haemolysis of RBCs, whereas acetyl salicylic acid inhibited 77.20%. On the
 276 other hand, during hypotonic solution induced haemolysis, CE inhibited 47.60% haemolysis of
 277 RBCs as compared to 71.90% produced by acetyl salicylic acid.

278




Figure 2:Heat induced haemolysis with standard deviation error bar




Figure 3:Hypotonic solution induced haemolysis with standard deviation error bar

279 *Antimicrobial assay*

280 Table-2 shows antimicrobial activity of the tested samples. PESF showed mild activity against
 281 gram negative bacteria *Escherichia coli* and *Pseudomonas aeruginosa*. CTCSF exhibited mild
 282 activity against both gram positive and gram negative bacteria. All the fractions were inactive
 283 against fungal strains. This result is consistent with some antimicrobial screening reports on the
 284 plant³⁵.

285 Table 2: Antimicrobial activity of test samples of *E. fluctuans*

Test organisms	Diameter of zone of inhibition(mm)				
	PESF 100µg/dis c	CTSF 100µg/di sc	CSF 100µg/di sc	AQSF 100µg/di sc	Ketoconazole 30µg/disc
Gram positive Bacteria					
<i>Bacillus megaterium</i>	–	7 mm	–	–	40 mm
<i>Staphylococcus aureus</i>	–	8 mm	–	–	28 mm
Gram negative Bacteria					
<i>Escherichia coli</i>	7 mm	8 mm	–	–	26 mm
<i>Pseudomonas aeruginosa</i>	7 mm	7 mm	–	–	27 mm
Fungal Strain					
<i>Aspergillusniger</i>	–	–	–	–	26 mm
<i>Aspergillusflavus</i>	–	–	–	–	36 mm

286

287 *Antioxidant assay*

288 The antioxidant activity was expressed from the IC₅₀ value of all samples. Comparison of IC₅₀
 289 values of different fractions and extracts with standard was shown in figure 4. AQSF was found
 290 to be most potent with lowest IC₅₀ value. IC₅₀ values of PESF, CTCSF, CSF, AQSF, trolox,
 291 BHA, Vitamin C are 59.59 µg/mL, 29.28 µg/mL, 26.62 µg/mL, 12.27 µg/mL, 2.04 µg/mL, 2.21
 292 µg/mL and 0.17 µg/mL respectively. Previous report of *E. fluctuans* collected from West Bengal,
 293 India suggests significant antioxidant property of ethyl acetate extract³⁶. Also there has been report
 294 of isolation of antioxidative carbohydrate polymer from *E. fluctuans* which is most consistent with
 295 our finding³⁷.

296




Figure 4: Comparison of LC₅₀ value of different extracts of *E. fluctuans* & standards.

297

298

299 *Cytotoxicity assay*

300 In case of brine shrimp lethality bioassay, the lethality of the PESF, CTCFSF, CSF and AQSF
 301 fractions against *A. salina* were shown in Table 3. Lethality assay is proved to be suggestive of
 302 different pharmacological properties by isolation of cytotoxic, antimalarial or insecticidal
 303 compounds from the cytotoxic plant extracts³⁸. Flavonoids isolated from *E. fluctuans* exhibited
 304 anticancer activity tested *in vitro* in mice³⁹. There is also report of *E. fluctuans* leaves stimulating
 305 cell-mediated immune system by increasing neutrophil's phagocytic activity⁴⁰. Here,
 306 CTCFSF fraction was most potent with the lowest LC₅₀ value which is consistent with the existing
 307 reports on *E. fluctuans*.

308 **Table 3:** Lethal concentration for 50% mortality (LC₅₀) of different extracts of *E. fluctuans*.

Sample	PESF	CTCSF	CSF	AQSF
LC ₅₀ value (µg/mL)	0.97	0.84	1.43	1.16

309 Preliminary chemical screening and *in-vitro* bioactivity study data suggests *Enhydra fluctuans*
 310 potential pharmacological activity. It showed significant cytotoxic activity with good
 311 thrombolytic and anti-inflammatory potential. Further higher and detailed experiments for
 312 isolation of bioactive compounds from *Enhydra fluctuans*.

313 **Conflict of Interest**

314 There is no conflict of interest to declare by the authors.

315

316 **References**

- 317 1. Davies MJ, Thomas AC. Plaque fissuring--the cause of acute myocardial infarction, sudden
 318 ischaemic death, and crescendo angina. *British Heart Journal* 1985; 53:363-373.
 319 2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang
 320 HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial
 321 infarction. *The New England Journal of Medicine* 1980; 303:897-902.
 322 3. Laurence DR, Bennett PN. *Clinical Pharmacology*. Ed 7, Churchill Livingstone, New York,
 323 1992.

- 324 4. Cochrane CG. Cellular injury by oxidants. American Journal of Medicine 1991;91: 23 – 30.
- 325 5. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxidative Medicine
326 and Cellular Longevity 2011; 2011:Article ID 809696.
- 327 6. Murugasan N, Vember S, Damodharan C. Studies on erythrocyte membrane IV: in vitro
328 haemolytic activity of oleander extract. Toxicology Letters 1981; 8:33-38.
- 329 7. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies.
330 Journal of Antimicrobial Chemotherapy 2002; 49:7-10.
- 331 8. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses.
332 Nature Medicine 2004; 10:122-129.
- 333 9. Taubes G. The bacteria fight back. Science 2008; 321: 356-361.
- 334 10. Levy SB. The antibiotic paradox-How miracle drugs are destroying the miracle. Plenum Press,
335 New York, 1992.
- 336 11. Levy SB. Antibiotic resistance: an ecological imbalance. In: Antibiotic Resistance: Origins,
337 Evolution, Selection and Spread, editors: Chadwick D, Goode J, John Wiley and Sons,
338 Chichester, 1997, 1-14.
- 339 12. Gutteridge JM. Free radicals in disease processes: A complication of cause and
340 consequence. Free Radical Research Communications 1993; 19(3):141-158.
- 341 13. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and diseases.
342 Journal of the American Oil Chemists' Society 1998; 75: 199-212.
- 343 14. Halliwell B. The antioxidant paradox. Lancet 2000; 355: 1179-1180.
- 344 15. Branen AL. Toxicology and biochemistry of butylated hydroxyanisole and
345 butylated hydroxytoluene. Journal of the American Oil Chemists' Society 1975; 5: 59-63.
- 346 16. Grice HP. Enhanced tumour development by butylated hydroxyanisole (BHA) from the
347 prospective of effect on fore-stomach and oesophageal squamous epithelium. Food and
348 Chemical Toxicology 1988; 26: 717-723.
- 349 17. Wichi HC. Safety evaluation of butylated hydroxytoluene (BHT) in the liver, lung and
350 gastrointestinal tract. Food and Chemical Toxicology 1986; 24: 1127-1130.
- 351 18. Persoone G. Proceeding of the International Symposium on Brine Shrimp, *Artemiasalina*.
352 Universa Press, Witteren, 1980, 1-3.
- 353 19. Meyer BN, Putnam JE, Jacobsen LB, Nichols DE, and McLaughlin JL. *Planta Medica* 1982;
354 45: 31-32.
- 355 20. Bora P, Kumar Y. Floristic diversity of Assam. Study of pabitorawildlife sanctuary. Daya
356 Publishing House, Delhi, 2003.
- 357 21. Nadkarni AK. The Indian materia medica. Vol. 2, Popular Prakashan, Bombay, 1999.
- 358 22. Kirtikar KR, Basu BD. Indian Medicinal Plants. Vol. 2, International Book Distributors, Dehra
359 Dun. 1999.
- 360 23. Chatterjee A, Pakrashi S. The treatise on Indian medicinal plants. Vol. 5, Publication and
361 Information Directorate, CSIR, Delhi. 1997.
- 362 24. Van Wagenen BC, Larsen R, Cardellina JHII, Ran dazzo D, Lidert ZC, Swithenbank C.
363 Ulosantoin a potent insecticide from the sponge *Ulosaruetzleri*. Journal of Organic
364 Chemistry 1993; 58: 335-337.
- 365 25. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: a
366 review. *Internationale Pharmaceutica Scientia* 2011; 1: 103-104.
- 367 26. Ahmed ZU, Bithi SS, Khan MM, Hossain MM, Suriya S, Rony SR. Phytochemical
368 screening, antioxidant and cytotoxic activity of fruit extracts of *Calamustenuis* Roxb. Journal
369 of Coastal Life Medicine. 2014; 2(8):645-50.

- 370 27. Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Dagainawala HF. Development
371 of an *in vitro* model to study clot lysis activity of thrombolytic drugs. *Thrombosis Journal*
372 2006; 4: 14.
- 373 28. Shinde UA, Phadke AS, Nair AM, Mungantiwar AA, Dikshit VJ, Saraf MN. Membrane
374 stabilizing activity - a possible mechanism of action for the anti-inflammatory activity of
375 *Cedrusdeodarawood* oil. *Fitoterapia* 1999; 70: 251-257.
- 376 29. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standard
377 single disc method. *American Journal of Clinical Pathology* 1966; 45: 493-96.
- 378 30. William WB, Cuvelier ME, Berset C. Use of Free Radical Method to Evaluate Antioxidant
379 Activity. *LWT-Food Science and Technology* 1995; 28(1): 25- 30.
- 380 31. Maclaughlin JL, Anderson JE, Rogers LL. The use of biological assays to evaluate
381 botanicals. *Drug Information Journal* 1998; 32: 513-524.
- 382 32. Omale J, Okafor PN. Comparative antioxidant capacity, membrane stabilization, polyphenol
383 composition and cytotoxicity of the leaf and stem of *Cissusmultistriata*. *African Journal of*
384 *Biotechnology* 2008; 7:3129-3133.
- 385 33. Shahriar M, Khair NZ, Sheikh Z, Chowdhury SF, Kamruzzaman M, Bakhtiar MSI *et al.*
386 Characterization of phytoconstituents and potential bioactivity of *Annonareticulata*L. leaf
387 extract. *Journal of Pharmacognosy and Phytochemistry* 2016; 5(1): 42-45.
- 388 34. Sannigrahi S, Mazumder UK, Pal D, Mishra SL, Maity S. Flavonoids of *EnhydraFluctuans*
389 exhibits analgesic and anti-inflammatory activity in different animal models. *Pakistan journal*
390 *of Pharmaceutical Sciences* 2011; 24(3): 369-375.
- 391 35. Bhakta J, Majumdar P, Munekage Y. Antimicrobial efficacies of methanol extract of
392 *Asteracanthalongifolia*, *Ipomoea aquatica* and *Enhydrafluctuans* against *Escherichia coli*,
393 *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Micrococcus luteus*. *Internet Journal*
394 *of Alternative Medicine* 2009;7(2).
- 395 36. Sannigrahi S, Mazuder UK, Pal DK, Parida S, Jain S. Antioxidant potential of crude extract
396 and different fractions of *Enhydrafluctuans*Lour. *Iranian journal of pharmaceutical*
397 *research* 2010;9(1):75.
- 398 37. Ghosh D, Ray S, Ghosh K, Micard V, Chatterjee UR, Ghosal PK, Ray B. Antioxidative
399 carbohydrate polymer from *Enhydrafluctuans* and its interaction with bovine serum albumin.
400 *Biomacromolecules* 2013; 14(6):1761-1768.
- 401 38. Krishnaraju AV, Rao TV, Sundararaju D, Vanisree M, Tsay HS, Subbaraju GV. Biological
402 screening of medicinal plants collected from Eastern Ghats of India using
403 *Artemiasalina*(brine shrimp test). *International Journal of Applied*
404 *Science and Engineering* 2006; 4(2):115-125.
- 405 39. Sannigrahi S, Mazumder UK, Mondal A, Pal D, Mishra SL, Roy S. Flavonoids of
406 *Enhydrafluctuans* exhibit anticancer activity against Ehrlich's ascites carcinoma in mice.
407 *Natural product communications*. 2010; 5(8):1239-1242.
- 408 40. Patil KS, Majumder P, Wadekar RR. Effect of *Enhydrafluctuans*Lour. leaf extract on
409 phagocytosis by human neutrophils. *Journal of Natural Remedies* 2008; 8(1):76-81.